Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron invested $119.5 million in Truveta’s Series C funding ... Truveta touts the endeavor as being more than 10 times the scale of other health care databases, such as the UK Biobank, which ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron pledged $119.5m while Illumina is ... interplay between genetics and health in unprecedented detail.” The UK Biobank, which holds genetic and health information from 500,000 ...

Regeneron invested $119.5 million in Truveta ... than 10 times the scale of other health care databases, such as the UK Biobank, which includes 500,000 participants recruited between 2006 ...